Importantly, both shikonin and TRAIL selectively kill cancer cells with minimal or no cytotoxicity to normal cells; therefore, combined treatment with shikonin and TRAIL may be an effective and safe strategy for cancer therapy. Here, TNFSF10 is linked to cancer.